logo
Plus   Neg
Share
Email

Halozyme's Cancer Drug Fails To Meet Primary Endpoint; To Cut Jobs

Halozyme Therapeutics, Inc. (HALO) said Monday that the HALO-301 late-stage clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival.

The company said it plans to halt development activities for PEGPH20 and and close its oncology operations. It will implement an organizational restructuring to focus its operations solely on its ENHANZE drug delivery technology.

The company noted that it will reduce headcount by about 55%, or 160 positions, with over 80% of the reduction completed in early January 2020.

The restructuring efforts will save $130 million to $140 million in 2020 compared with the Company's most recent guidance for 2019 operating expenses excluding cost of goods sold.

Halozyme anticipates becoming a sustainably profitable company beginning in the second quarter of 2020.

The company expects to book separation and contract termination fees in the fourth quarter of 2019.

Halozyme's Board authorized the company to repurchase up to $350 million of the Company's outstanding common stock over the next three years.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT